Cargando…

Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer

BACKGROUND: How to evaluate the prognosis and develop overall treatment strategies of metachronous bilateral breast cancer (MBBC) remains confused in clinical. Here, we investigated the correlation between clonal evolution and clinical characteristics of MBBC; we aim to establish a novel prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lingyu, Li, Jiaxuan, Jia, Jiwei, He, Hua, Li, Mingyang, Yan, Xu, Yu, Qing, Guo, Hanfei, Wang, Hong, Lv, Zheng, Sun, Haishuang, Liao, Guidong, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559188/
https://www.ncbi.nlm.nih.gov/pubmed/36249030
http://dx.doi.org/10.3389/fonc.2022.963884
_version_ 1784807601600462848
author Li, Lingyu
Li, Jiaxuan
Jia, Jiwei
He, Hua
Li, Mingyang
Yan, Xu
Yu, Qing
Guo, Hanfei
Wang, Hong
Lv, Zheng
Sun, Haishuang
Liao, Guidong
Cui, Jiuwei
author_facet Li, Lingyu
Li, Jiaxuan
Jia, Jiwei
He, Hua
Li, Mingyang
Yan, Xu
Yu, Qing
Guo, Hanfei
Wang, Hong
Lv, Zheng
Sun, Haishuang
Liao, Guidong
Cui, Jiuwei
author_sort Li, Lingyu
collection PubMed
description BACKGROUND: How to evaluate the prognosis and develop overall treatment strategies of metachronous bilateral breast cancer (MBBC) remains confused in clinical. Here, we investigated the correlation between clonal evolution and clinical characteristics of MBBC; we aim to establish a novel prognostic model in these patients. METHODS: The data from Surveillance, Epidemiology, and End Results (SEER) database and the First Hospital of Jilin University were analyzed for breast cancer–specific cumulative mortality (BCCM) by competing risk model. Meanwhile, whole-exome sequencing was applied for 10 lesions acquired at spatial–temporal distinct regions of five patients from our own hospital to reconstruct clonal evolutionary characteristics of MBBC. Then, dimensional-reduction (DR) cumulative incidence function (CIF) curves of MBBC features were established on different point in diagnostic interval time, to build a novel DR nomogram. RESULTS: Significant heterogeneity in genome and clinical features of MBBC was widespread. The mutational diversity of contralateral BC (CBC) was significantly higher than that in primary BC (PBC), and the most effective prognostic MATH ratio was significantly correlated with interval time (R (2) = 0.85, p< 0.05). In SEER cohort study (n = 13,304), the interval time was not only significantly affected the BCCM by multivariate analysis (p< 0.000) but determined the weight of clinical features (T/N stage, grade and ER status) on PBC and CBC in prognostic evaluation. Thus, clinical parameters after DR based on interval time were incorporated into the nomogram for prognostic predicting BCCM. Concordance index was 0.773 (95% CI, 0.769–0.776) in training cohort (n = 8,869), and 0.819 (95% CI, 0.813–0.826) in validation cohort (n = 4,435). CONCLUSIONS: Bilateral heterogeneous characteristics and interval time were determinant prognostic factors of MBBC. The DR prognostic nomogram may help clinicians in prognostic evaluation and decision making.
format Online
Article
Text
id pubmed-9559188
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95591882022-10-14 Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer Li, Lingyu Li, Jiaxuan Jia, Jiwei He, Hua Li, Mingyang Yan, Xu Yu, Qing Guo, Hanfei Wang, Hong Lv, Zheng Sun, Haishuang Liao, Guidong Cui, Jiuwei Front Oncol Oncology BACKGROUND: How to evaluate the prognosis and develop overall treatment strategies of metachronous bilateral breast cancer (MBBC) remains confused in clinical. Here, we investigated the correlation between clonal evolution and clinical characteristics of MBBC; we aim to establish a novel prognostic model in these patients. METHODS: The data from Surveillance, Epidemiology, and End Results (SEER) database and the First Hospital of Jilin University were analyzed for breast cancer–specific cumulative mortality (BCCM) by competing risk model. Meanwhile, whole-exome sequencing was applied for 10 lesions acquired at spatial–temporal distinct regions of five patients from our own hospital to reconstruct clonal evolutionary characteristics of MBBC. Then, dimensional-reduction (DR) cumulative incidence function (CIF) curves of MBBC features were established on different point in diagnostic interval time, to build a novel DR nomogram. RESULTS: Significant heterogeneity in genome and clinical features of MBBC was widespread. The mutational diversity of contralateral BC (CBC) was significantly higher than that in primary BC (PBC), and the most effective prognostic MATH ratio was significantly correlated with interval time (R (2) = 0.85, p< 0.05). In SEER cohort study (n = 13,304), the interval time was not only significantly affected the BCCM by multivariate analysis (p< 0.000) but determined the weight of clinical features (T/N stage, grade and ER status) on PBC and CBC in prognostic evaluation. Thus, clinical parameters after DR based on interval time were incorporated into the nomogram for prognostic predicting BCCM. Concordance index was 0.773 (95% CI, 0.769–0.776) in training cohort (n = 8,869), and 0.819 (95% CI, 0.813–0.826) in validation cohort (n = 4,435). CONCLUSIONS: Bilateral heterogeneous characteristics and interval time were determinant prognostic factors of MBBC. The DR prognostic nomogram may help clinicians in prognostic evaluation and decision making. Frontiers Media S.A. 2022-09-29 /pmc/articles/PMC9559188/ /pubmed/36249030 http://dx.doi.org/10.3389/fonc.2022.963884 Text en Copyright © 2022 Li, Li, Jia, He, Li, Yan, Yu, Guo, Wang, Lv, Sun, Liao and Cui https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Lingyu
Li, Jiaxuan
Jia, Jiwei
He, Hua
Li, Mingyang
Yan, Xu
Yu, Qing
Guo, Hanfei
Wang, Hong
Lv, Zheng
Sun, Haishuang
Liao, Guidong
Cui, Jiuwei
Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer
title Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer
title_full Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer
title_fullStr Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer
title_full_unstemmed Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer
title_short Clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer
title_sort clonal evolution characteristics and reduced dimension prognostic model for non-metastatic metachronous bilateral breast cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559188/
https://www.ncbi.nlm.nih.gov/pubmed/36249030
http://dx.doi.org/10.3389/fonc.2022.963884
work_keys_str_mv AT lilingyu clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer
AT lijiaxuan clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer
AT jiajiwei clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer
AT hehua clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer
AT limingyang clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer
AT yanxu clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer
AT yuqing clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer
AT guohanfei clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer
AT wanghong clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer
AT lvzheng clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer
AT sunhaishuang clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer
AT liaoguidong clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer
AT cuijiuwei clonalevolutioncharacteristicsandreduceddimensionprognosticmodelfornonmetastaticmetachronousbilateralbreastcancer